At the Jefferies Global Healthcare Conference in London on November 18, Compass Pathways said it has strong confidence it can and should price COMP360 at a premium to Johnson & Johnson’s Spravato on an annualized basis. COMP360, its synthetic psilocybin for treatment-resistant depression, is investigational: Compass completed its new drug application on November 9, FDA has not approved it, and, by management’s account, the FDA safety program that would set monitoring requirements for treatment sites has not been finalized.

A week earlier, at a different conference, the company had said it had not set a price and would price to the value the drug brings, with the marketed product as a reference. In October, STAT reported, the chief executive had declined to commit to a benchmark. Management offered one basis for the position, market research with payers whose results it did not describe, and Compass has still not set a price.

A premium is a position, not a price. Two estimates carry it: what a year of Spravato costs, which Compass computed itself, and how many doses COMP360 patients will need, which management expects and the trials bound only by maximums. A separate uncertainty sits outside the price: management says payers have not yet valued an hourly rate for monitoring psychedelic treatment, which bears on what sites earn from offering it.

Estimate one: what a year of Spravato costs

Management put Spravato’s annualized cost at $50,000 to $65,000, a range it tied to the drug’s two dose strengths and its maintenance schedules, and said COMP360 should need two to four doses a year against 35 to 55 for Spravato. Spravato is sold per treatment dose, and Compass did not say whether its annual range reflects list or net prices. The figure describes a full year for a patient who stays on schedule, so it is a regimen cost, not an average.

Management’s own scale figures show the distance. It described Spravato as on track for more than $2 billion in sales this year across about 100,000 patients, which implies on the order of $20,000 per patient, though management did not say whether the sales and patient figures cover the same geography and period. The two numbers answer different questions: the range describes a full year on the schedule, while sales per patient reflect rebates, partial years and discontinuation. A premium to the range is a premium to the cost of a full year on schedule, not to what Spravato earns per patient on average. Compass did not say which measure payers will use.

Estimate two: how many doses COMP360 patients need

The two-to-four-dose range is management’s expectation, not an observed annual dosing distribution. The trials permitted up to three or four doses, but those limits do not establish how many doses patients typically received. According to Compass’s July 7 results release, COMP006 allowed up to four doses over 52 weeks and COMP005 up to three. Compass’s results deck of the same date reported that 58 percent of the COMP006 25 mg arm received retreatment after Week 9, with either study drug or an antidepressant, so the figure does not isolate COMP360 doses. The deck also described durability through six months with one or two additional doses after the initial dose. Neither the deck nor the release gives doses received through Week 52, when the open-label part ends.

Management also described COMP360’s efficacy and tolerability as fairly comparable to Spravato’s. No registered trial compares the two, so the premium case rests on fewer visits, not on demonstrated better outcomes.

Dividing Spravato’s $50,000 to $65,000 by the dose count shows what a premium would require. These are break-even figures built from management’s own ranges, not Compass pricing, and any price per dose above them would be a premium:

  • Four doses a year: $12,500 to $16,250 a dose would match Spravato’s range.
  • Two doses a year: $25,000 to $32,500 a dose would match it.

Revenue per patient follows the dose count, so a label price alone says little about what each patient is worth to Compass.

A separate question: what sites are paid

Management described Spravato appointments as at least three hours and COMP360 monitoring time as six. As illustrative arithmetic on those assumptions, not observed utilization, a Spravato patient on 35 to 55 appointments spends 105 to 165 hours a year in them and a COMP360 patient on two to four sessions spends 12 to 24, about 87 percent fewer at the midpoints.

Management said its goal at launch is that sites not be disadvantaged against the hourly rate Spravato sites receive today, and that payers have not yet valued an hourly rate for monitoring psychedelic treatment. Until then, it said, sites would bill existing evaluation and management codes, the visit-based codes Spravato sites use, with added increments for time beyond two hours. It also said it expects the monitoring codes created for psychedelic treatment to move from Category III to Category I status within 12 to 18 months. Category III codes are temporary codes the American Medical Association issues to track new services, and whether to pay for them, and how much, is left to each payer. Category I codes are permanent, but the AMA says a CPT code does not guarantee coverage, reimbursement or payment. A code’s existence, or its conversion, does not establish that any payer will pay for monitoring.

Management framed the goal in hourly terms, while Spravato sites bill by visit. Illustratively, if payment per hour matched Spravato’s, a site would need about seven and a half COMP360 patients to bill the same number of hours as one Spravato patient. That is arithmetic on management’s assumptions, not an established reimbursement outcome. Not being disadvantaged per hour is not the same as per patient.

Capacity may not be the constraint

Management said the average Spravato site sees about one Spravato patient a day and has capacity, while acknowledging that volume is concentrated at the high end. An average cannot show whether capacity sits in busy clinics or idle ones. Compass counts about 8,500 sites, growing by about 500 a quarter, and expects more than 9,000 at launch. No independent count was located, and Behavioral Wire has examined how little of that clinic base’s terms are public. On management’s dosing assumptions each patient uses far fewer room hours than a Spravato patient. What may limit a site is whether six-hour sessions are paid and whether enough patients arrive to fill them.

Drug payment and site payment are separate problems

Management expects payers to place the drug under an NDC block at first, meaning a payer declines to cover a specific drug until it finishes its review. On November 11 it said supply would run through specialty pharmacy, with buy-and-bill enabled, in which a clinic buys the drug and bills for it. Management described an affordability program that keeps drug cost off patients while coverage is pending. It treated drug payment and monitoring payment as separate claims and did not say whether payers that block the drug will pay for the monitoring.

Compass has said where it believes it can price relative to Spravato. It has not said what it will charge, how many doses a typical patient will need, or what a site will be paid for the hours.